AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 26-50/173
TREATMENT OF CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: LIESNER R GOLDSTONE AH
Citation: R. Liesner et Ah. Goldstone, TREATMENT OF CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA, Journal of internal medicine, 242, 1997, pp. 29-36
EXPRESSION OF CD25 (INTERLEUKIN-2 RECEPTOR-ALPHA CHAIN) IN ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA PREDICTS FOR THE PRESENCE OF BCR ABL FUSION TRANSCRIPTS - RESULTS OF A PRELIMINARY LABORATORY ANALYSIS OF ECOG/MRC INTERGROUP STUDY E2993/
Authors: PAIETTA E RACEVSKIS J NEUBERG D ROWE JM GOLDSTONE AH WIERNIK PH
Citation: E. Paietta et al., EXPRESSION OF CD25 (INTERLEUKIN-2 RECEPTOR-ALPHA CHAIN) IN ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA PREDICTS FOR THE PRESENCE OF BCR ABL FUSION TRANSCRIPTS - RESULTS OF A PRELIMINARY LABORATORY ANALYSIS OF ECOG/MRC INTERGROUP STUDY E2993/, Leukemia, 11(11), 1997, pp. 1887-1890
ROLE OF A 2ND TRANSPLANT IN THE MANAGEMENT OF POOR-PROGNOSIS LYMPHOMAS - A REPORT FROM THE EUROPEAN BLOOD AND BONE-MARROW REGISTRY
Authors: VANDENBERGHE E PEARCE R TAGHIPOUR G FOUILLARD L GOLDSTONE AH
Citation: E. Vandenberghe et al., ROLE OF A 2ND TRANSPLANT IN THE MANAGEMENT OF POOR-PROGNOSIS LYMPHOMAS - A REPORT FROM THE EUROPEAN BLOOD AND BONE-MARROW REGISTRY, Journal of clinical oncology, 15(4), 1997, pp. 1595-1600
PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION VERSUS AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS AND NON-HODGKINS-LYMPHOMAS - A NEW MATCHED-PAIR ANALYSIS OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION REGISTRY DATA
Authors: MAJOLINO I PEARCE R TAGHIPOUR G GOLDSTONE AH
Citation: I. Majolino et al., PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION VERSUS AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS AND NON-HODGKINS-LYMPHOMAS - A NEW MATCHED-PAIR ANALYSIS OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION REGISTRY DATA, Journal of clinical oncology, 15(2), 1997, pp. 509-517
PROGENITOR-CELL MOBILIZATION AFTER LOW-DOSE CYCLOPHOSPHAMIDE AND GRANULOCYTE-COLONY-STIMULATING FACTOR - AN ANALYSIS OF PROGENITOR-CELL QUANTITY AND QUALITY AND FACTORS PREDICTING FOR THESE PARAMETERS IN 101 PRETREATED PATIENTS WITH MALIGNANT-LYMPHOMA
Authors: WATTS MJ SULLIVAN AM JAMIESON E PEARCE R FIELDING A DEVEREUX S GOLDSTONE AH LINCH DC
Citation: Mj. Watts et al., PROGENITOR-CELL MOBILIZATION AFTER LOW-DOSE CYCLOPHOSPHAMIDE AND GRANULOCYTE-COLONY-STIMULATING FACTOR - AN ANALYSIS OF PROGENITOR-CELL QUANTITY AND QUALITY AND FACTORS PREDICTING FOR THESE PARAMETERS IN 101 PRETREATED PATIENTS WITH MALIGNANT-LYMPHOMA, Journal of clinical oncology, 15(2), 1997, pp. 535-546
ECONOMIC-ANALYSIS OF A RANDOMIZED CLINICAL-TRIAL TO COMPARE FILGRASTIM-MOBILIZED PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH HODGKINS AND NON-HODGKINS-LYMPHOMA
Authors: SMITH TJ HILLNER BE SCHMITZ N LINCH DC DREGER P GOLDSTONE AH BOOGAERTS MA FERRANT A LINK H ZANDER A YANOVICH S KITCHIN R ERDER MH
Citation: Tj. Smith et al., ECONOMIC-ANALYSIS OF A RANDOMIZED CLINICAL-TRIAL TO COMPARE FILGRASTIM-MOBILIZED PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH HODGKINS AND NON-HODGKINS-LYMPHOMA, Journal of clinical oncology, 15(1), 1997, pp. 5-10
CATARACTS FOLLOWING BONE-MARROW TRANSPLANTATION (BMT) CONDITIONED WITH TOTAL-BODY IRRADIATION (TBI) FOR ACUTE-LEUKEMIA (AL) IN COMPLETE REMISSION (CR) - A STUDY OF THE UROPEAN-GROUP-FOR-BLOOD-AND-MARROW-TRANSPLANTATION
Authors: BELKACEMI Y LABOPIN M VERNANT JP PRENTICE HG TICHELLI A DEWITTE T BOOGAERTS MA ERNST P DELLAVOLPE A GOLDSTONE AH JOUET JP VERDONCK LF RIO B LOCASCIULLI A OZSAHIN M GORIN NC
Citation: Y. Belkacemi et al., CATARACTS FOLLOWING BONE-MARROW TRANSPLANTATION (BMT) CONDITIONED WITH TOTAL-BODY IRRADIATION (TBI) FOR ACUTE-LEUKEMIA (AL) IN COMPLETE REMISSION (CR) - A STUDY OF THE UROPEAN-GROUP-FOR-BLOOD-AND-MARROW-TRANSPLANTATION, International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 175-175
HIGH-DOSE THERAPY AND AUTOLOGOUS STEM-CELL RESCUE FOR PATIENTS WITH HODGKINS-DISEASE IN FIRST RELAPSE AFTER CHEMOTHERAPY - RESULTS FROM THEEBMT
Authors: SWEETENHAM JW TAGHIPOUR G MULLIGAN D BLYSTAD AK CABALLERO D FASSAS A GOLDSTONE AH
Citation: Jw. Sweetenham et al., HIGH-DOSE THERAPY AND AUTOLOGOUS STEM-CELL RESCUE FOR PATIENTS WITH HODGKINS-DISEASE IN FIRST RELAPSE AFTER CHEMOTHERAPY - RESULTS FROM THEEBMT, Bone marrow transplantation, 20(9), 1997, pp. 745-752
EVALUATION OF CLINICAL-SCALE CD34(- EXPERIENCE OF 71 IMMUNOAFFINITY COLUMN PROCEDURES() CELL PURIFICATION )
Authors: WATTS MJ SULLIVAN AM INGS SJ LEVERETT D PENIKET AJ PERRY AR WILLIAMS CD DEVEREUX S GOLDSTONE AH LINCH DC
Citation: Mj. Watts et al., EVALUATION OF CLINICAL-SCALE CD34(- EXPERIENCE OF 71 IMMUNOAFFINITY COLUMN PROCEDURES() CELL PURIFICATION ), Bone marrow transplantation, 20(2), 1997, pp. 157-162
INCIDENCE OF AML1 ETO FUSION TRANSCRIPTS IN PATIENTS ENTERED INTO THEMRC AML TRIALS/
Authors: LANGABEER SE WALKER H ROGERS JR BURNETT AK WHEATLEY K SWIRSKY D GOLDSTONE AH LINCH DC
Citation: Se. Langabeer et al., INCIDENCE OF AML1 ETO FUSION TRANSCRIPTS IN PATIENTS ENTERED INTO THEMRC AML TRIALS/, British Journal of Haematology, 99(4), 1997, pp. 925-928
G-CSF AFTER PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN LYMPHOMA PATIENTS SIGNIFICANTLY ACCELERATED NEUTROPHIL RECOVERY AND SHORTENED TIME IN-HOSPITAL - RESULTS OF A RANDOMIZED BNLI TRIAL
Authors: LINCH DC MILLIGAN DW WINFIELD DA KELSEY SM JOHNSON SA LITTLEWOOD TJ SMITH GM HUTCHINSON RM GOLDSTONE AH FIELDING AK HUDSON GV
Citation: Dc. Linch et al., G-CSF AFTER PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN LYMPHOMA PATIENTS SIGNIFICANTLY ACCELERATED NEUTROPHIL RECOVERY AND SHORTENED TIME IN-HOSPITAL - RESULTS OF A RANDOMIZED BNLI TRIAL, British Journal of Haematology, 99(4), 1997, pp. 933-938
FREQUENCY OF CBF-BETA MYH11 FUSION TRANSCRIPTS IN PATIENTS ENTERED INTO THE UK MRC AML TRIALS/
Authors: LANGABEER SE WALKER H GALE RE WHEATLEY K BURNETT AK GOLDSTONE AH LINCH DC
Citation: Se. Langabeer et al., FREQUENCY OF CBF-BETA MYH11 FUSION TRANSCRIPTS IN PATIENTS ENTERED INTO THE UK MRC AML TRIALS/, British Journal of Haematology, 96(4), 1997, pp. 736-739
TREATMENT OF CHRONIC MYELOID-LEUKEMIA IN FIRST CHRONIC PHASE WITH IDARUBICIN AND CYTARABINE - MOBILIZATION OF PHILADELPHIA-NEGATIVE PERIPHERAL-BLOOD STEM-CELLS
Authors: CHALMERS EA FRANKLIN IM KELSEY SR NEWLAND AC CLARK RE SPROUL AN CROTTY G MCCANN SR FIELDING A GOLDSTONE AH HEPPLESTONE A WATSON W SHARP RA TANSEY P
Citation: Ea. Chalmers et al., TREATMENT OF CHRONIC MYELOID-LEUKEMIA IN FIRST CHRONIC PHASE WITH IDARUBICIN AND CYTARABINE - MOBILIZATION OF PHILADELPHIA-NEGATIVE PERIPHERAL-BLOOD STEM-CELLS, British Journal of Haematology, 96(3), 1997, pp. 627-634
2 THIRDS OF ADULT PATIENTS (PTS) WITH LYMPHOMA ACHIEVE LONG-TERM SURVIVAL AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION (BMT) - RESULTS FROM THE EBMT
Authors: SWEETENHAM JW BIERMAN P TAGHIPOUR G GRATWOHL A HAGENBEEK A GREINIX H SCHAEFER UW GOLDSTONE AH
Citation: Jw. Sweetenham et al., 2 THIRDS OF ADULT PATIENTS (PTS) WITH LYMPHOMA ACHIEVE LONG-TERM SURVIVAL AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION (BMT) - RESULTS FROM THE EBMT, Blood, 90(10), 1997, pp. 4512-4512
THE LENGTH OF THE FIRST COMPLETE REMISSION (1-6 MONTHS, 7-12 MONTHS GREATER-THAN-12 MONTHS) DOES NOT PREDICT OUTCOME FOLLOWING BEAM AND AUTOTRANSPLANTATION FOR HODGKINS-DISEASE IN FIRST RELAPSE
Authors: KOTTARIDIS PD PENIKET AJ PERRY AR HARRISON CN DEELVIRA MCR MACMILLAN A DEVEREUX S LINCH DC GOLDSTONE AH
Citation: Pd. Kottaridis et al., THE LENGTH OF THE FIRST COMPLETE REMISSION (1-6 MONTHS, 7-12 MONTHS GREATER-THAN-12 MONTHS) DOES NOT PREDICT OUTCOME FOLLOWING BEAM AND AUTOTRANSPLANTATION FOR HODGKINS-DISEASE IN FIRST RELAPSE, Blood, 90(10), 1997, pp. 496-496
OUTCOME OF BEAM AUTOTRANSPLANTATION IN PATIENTS WITH HODGKINS-DISEASEPROGRESSING ON FIRST LINE THERAPY IS THE SAME AS IN PATIENTS TRANSPLANTED IN FIRST PARTIAL REMISSION
Authors: PENIKET AJ KOTTARIDIS PD PERRY AR DEELVIRA MCR DEVEREUX S MACMILLAN A GOLDSTONE AH LINCH DC
Citation: Aj. Peniket et al., OUTCOME OF BEAM AUTOTRANSPLANTATION IN PATIENTS WITH HODGKINS-DISEASEPROGRESSING ON FIRST LINE THERAPY IS THE SAME AS IN PATIENTS TRANSPLANTED IN FIRST PARTIAL REMISSION, Blood, 90(10), 1997, pp. 497-497
BACKUP BONE-MARROW IS FREQUENTLY INEFFECTIVE IN PATIENTS WITH POOR PERIPHERAL-BLOOD PROGENITOR-CELL MOBILIZATION
Authors: WATTS MJ SULLIVAN AM LEVERETT D PENIKET AJ WILLIAMS CD DEVEREUX S GOLDSTONE AH LINCH DC
Citation: Mj. Watts et al., BACKUP BONE-MARROW IS FREQUENTLY INEFFECTIVE IN PATIENTS WITH POOR PERIPHERAL-BLOOD PROGENITOR-CELL MOBILIZATION, Blood, 90(10), 1997, pp. 938-938
AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR T-CELL AND NULL-CELL TYPES CD-30 POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA - PRELIMINARY-ANALYSIS OF65 CASES REPORTED TO THE EBMT
Authors: FAMIN R SILVESTRI F DEELVIRA MCR TAGHIPOUR G SPEROTTO A GOLDSTONE AH
Citation: R. Famin et al., AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR T-CELL AND NULL-CELL TYPES CD-30 POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA - PRELIMINARY-ANALYSIS OF65 CASES REPORTED TO THE EBMT, Blood, 90(10), 1997, pp. 1021-1021
ALLOGENIC TRANSPLANTATION FOR LYMPHOMA PRODUCES A LOWER RELAPSE RATE THAN AUTOLOGOUS TRANSPLANTATION BUT SURVIVAL IS WORSE BECAUSE OF HIGHER TREATMENT RELATED MORTALITY - A REPORT OF 764 CASES FROM THE EBMT LYMPHOMA REGISTRY
Authors: PENIKET AJ DEELVIRA MCR TAGHIPOUR G DEWITTE T TAZELAAR PJ CARELLA A VERNANT JP SCHAEFER UW CLEEVEN M BOOGAERTS MA GLUCKMAN E GOLDSTONE AH
Citation: Aj. Peniket et al., ALLOGENIC TRANSPLANTATION FOR LYMPHOMA PRODUCES A LOWER RELAPSE RATE THAN AUTOLOGOUS TRANSPLANTATION BUT SURVIVAL IS WORSE BECAUSE OF HIGHER TREATMENT RELATED MORTALITY - A REPORT OF 764 CASES FROM THE EBMT LYMPHOMA REGISTRY, Blood, 90(10), 1997, pp. 1121-1121
ALL TRANSRETINOIC ACID GIVEN CONCURRENTLY WITH INDUCTION CHEMOTHERAPYIMPROVES THE OUTCOME OF APL - RESULTS OF THE UK MRC ATRA TRIAL
Authors: BURNETT AK GOLDSTONE AH GRAY RG WHEATLEY K
Citation: Ak. Burnett et al., ALL TRANSRETINOIC ACID GIVEN CONCURRENTLY WITH INDUCTION CHEMOTHERAPYIMPROVES THE OUTCOME OF APL - RESULTS OF THE UK MRC ATRA TRIAL, Blood, 90(10), 1997, pp. 1474-1474
WHICH PBPC PATIENTS MAY BENEFIT FROM ACCELERATED PLATELET RECOVERY - FACTORS AFFECTING HOSPITAL DISCHARGE IN 152 CONSECUTIVE PATIENTS, THE RELEVANCE OF CD34 DOSE AND THE POTENTIAL IMPLICATIONS OF MEGAKARYOCYTEGROWTH-FACTOR
Authors: PENIKET AJ PERRY AR LEVERETT D WATTS M SULLIVAN A LINCH DC GOLDSTONE AH
Citation: Aj. Peniket et al., WHICH PBPC PATIENTS MAY BENEFIT FROM ACCELERATED PLATELET RECOVERY - FACTORS AFFECTING HOSPITAL DISCHARGE IN 152 CONSECUTIVE PATIENTS, THE RELEVANCE OF CD34 DOSE AND THE POTENTIAL IMPLICATIONS OF MEGAKARYOCYTEGROWTH-FACTOR, Blood, 90(10), 1997, pp. 1701-1701
OUTCOME OF ACUTE MYELOID LEUKEMIAS AFFECTING CORE BINDING-FACTOR SUBUNITS - THE UK MRC EXPERIENCE
Authors: BURNETT AK WHEATLEY K LANGABEER S WALKER H LINCH D GOLDSTONE AH HANN I STEVENS RF
Citation: Ak. Burnett et al., OUTCOME OF ACUTE MYELOID LEUKEMIAS AFFECTING CORE BINDING-FACTOR SUBUNITS - THE UK MRC EXPERIENCE, Blood, 90(10), 1997, pp. 1737-1737
2522 AUTOTRANSPLANTS IN MULTIPLE-MYELOMA - A REGISTRY STUDY FROM THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT)
Authors: BJORKSTRAND B SVENSSON K LJUNGMAN P APPERLEY J GOLDSCHMIDT H REMES K ALEGRE A MARCUS R CARLSON K COSER P SUREDA A BARBUI T GOLDSTONE AH BLADE J VOLIN L BOOGAERTS M LENHOFF S MAJOLINO I SAMSON D DELAURENZI A CABALLERO D GAHRTON G
Citation: B. Bjorkstrand et al., 2522 AUTOTRANSPLANTS IN MULTIPLE-MYELOMA - A REGISTRY STUDY FROM THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT), Blood, 90(10), 1997, pp. 1862-1862
PREEMPTIVE ANTI-CMV THERAPY DURING ALLOGENEIC BONE-MARROW TRANSPLANTATION BASED UPON BLOOD PCR SURVEILLANCE PRODUCES MOLECULAR EVIDENCE OF EFFECTIVE VIRAL CLEARANCE WITH ABSENCE OF CLINICALLY DETECTABLE DISEASE
Authors: PENIKET AJ HOWARD MR PREISER W PERRY AR KOTTARIDIS PD MCKEAG N BRINK NS MACKINNON S GOLDSTONE AH
Citation: Aj. Peniket et al., PREEMPTIVE ANTI-CMV THERAPY DURING ALLOGENEIC BONE-MARROW TRANSPLANTATION BASED UPON BLOOD PCR SURVEILLANCE PRODUCES MOLECULAR EVIDENCE OF EFFECTIVE VIRAL CLEARANCE WITH ABSENCE OF CLINICALLY DETECTABLE DISEASE, Blood, 90(10), 1997, pp. 2423-2423
LACK OF BENEFIT OF G-CSF ON COMPLETE REMISSION AND POSSIBLE INCREASEDRELAPSE RISK IN AML - AN MRC STUDY OF 800 PATIENTS
Authors: GOLDSTONE AH BURNETT AK MILLIGAN DW PRENTICE AG WHEATLEY K
Citation: Ah. Goldstone et al., LACK OF BENEFIT OF G-CSF ON COMPLETE REMISSION AND POSSIBLE INCREASEDRELAPSE RISK IN AML - AN MRC STUDY OF 800 PATIENTS, Blood, 90(10), 1997, pp. 2595-2595
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>